Stock A302440 SK BIOSCIENCE CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

SK bioscience Co.,Ltd. Stock

Equities

A302440

KR7302440003

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
51,700 KRW -1.34% Intraday chart for SK bioscience Co.,Ltd. -8.66% -28.19%
May. 03 SK Bioscience's Attributable Loss Narrows in Q1 MT
Mar. 28 SK Bioscience Signs Deal with Sanofi for Five Vaccine Types MT

Financials

Sales 2024 * 242B 175M Sales 2025 * 325B 234M Capitalization 3,972B 2.87B
Net income 2024 * -37B -26.71M Net income 2025 * -17B -12.27M EV / Sales 2024 * 11.3 x
Net cash position 2024 * 1,242B 897M Net cash position 2025 * 663B 479M EV / Sales 2025 * 10.2 x
P/E ratio 2024 *
-106 x
P/E ratio 2025 *
-225 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 31.48%
More Fundamentals * Assessed data

Chart SK bioscience Co.,Ltd.

Dynamic Chart

Latest news about SK bioscience Co.,Ltd.

SK Bioscience's Attributable Loss Narrows in Q1 MT
SK Bioscience Signs Deal with Sanofi for Five Vaccine Types MT
SK Bioscience Breaks Ground on Manufacturing Facility Expansion for Extending Product Pipeline CI
SK Bioscience Obtains Prequalification Certification from the World Health Organization CI
SK Bioscience's Net Income Plunges in Q4 MT
SK Bioscience to Expand Facilities to Develop New Pneumococcal Vaccine MT
SK Group Advances Net Zero Transition via Key Renewable Energy Deal MT
SK Bioscience, Hilleman Laboratories Partner on Second-Gen Ebola Virus Vaccine MT
SK Bioscience Partners with Australian Company to Collaborate on Patch-Type Typhoid Vaccine Development MT
SK Bioscience Set to Deliver 5 Million Doses of Innovative Cell-Based Flu Vaccine SKYCellflu MT
SK Bioscience Boosts Partnership with Novavax via Acquisition of 6.5 Million Shares MT
Novavax, Inc. announced that it expects to receive $84.5 million in funding from SK bioscience Co.,Ltd. CI
S.Korean shares hit 14-month high on platform, biopharma boost RE
SK Bioscience Swings to Loss in Q2 MT
S.Korean shares end flat in wait-and-see mood; earnings, Fed in focus RE
More news

Analyst Recommendations on SK bioscience Co.,Ltd.

South Korean Stocks Close Flat After Fed Rate Hike; SK Bioscience Rises 16% MT
S.Korean stocks, won drop on Fed rate-hike bets, China slowdown fears RE
South Korea’s Kospi Declines 1% on Russia-Ukraine Conflict, Possible US Fed Rate Hikes; SK Bioscience Plunges 10% MT
More recommendations

Press releases SK bioscience Co.,Ltd.

Varicella Zoster Infections Pipeline Landscape Analysis of 03+ Companies by DelveInsight | Leading Companies - Curevo Vaccine, GeneOne Life Science, SK Bioscience, and Others AQ
SK bioscience : Material Business Matters Related to Investment Decisions (Approval of change of domestic product license for Novavax Corona 19 vaccine (addition of indications for adolescents aged 12 to 17)) PU
South Korea, Gates Foundation in deal to prepare for 'next pandemic' AQ
SK bioscience : Material Business Matters Related to Investment Decisions (Investigational new drug (IND) application for phase III clinical trial of heterologous booster shot of GBP510 in Nepal) PU
SK bioscience : Material Business Matters Related to Investment Decisions (Application for EMA conditional marketing authorization (CMA) for COVID-19 vaccine, SKYCovion(GBP510)) PU
More press releases

News in other languages on SK bioscience Co.,Ltd.

MÄRKTE ASIEN/Uneinheitlich - Preisdaten dämpfen Stimmung in China
MÄRKTE ASIEN/Börsen uneinheitlich mit leicht positivem Trend
4 minutos de mercados : Febrero 10-2023
4 minutos de mercados : Febrero 9-2023
4 minutos de mercados : Febrero 8-2023
More news

Quotes and Performance

1 day-1.34%
1 week-8.66%
1 month-11.77%
3 months-15.80%
6 months-23.75%
Current year-28.19%
More quotes

Highs and lows

1 week
51 700.00
Extreme 51700
56 900.00
1 month
51 700.00
Extreme 51700
61 900.00
Current year
51 700.00
Extreme 51700
73 700.00
1 year
51 700.00
Extreme 51700
88 600.00
3 years
51 700.00
Extreme 51700
362 000.00
5 years
51 700.00
Extreme 51700
362 000.00
10 years
51 700.00
Extreme 51700
362 000.00
More quotes

Managers and Directors - SK bioscience Co.,Ltd.

Managers TitleAgeSince
Jae-Yong An CEO
 Chief Executive Officer 56 -
Yong-Sung Choi DFI
 Director of Finance/CFO 51 -
Sally Choe CTO
 Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Jeffrey Choi BRD
 Director/Board Member 60 -
Chang-Jin Moon BRD
 Director/Board Member 71 -
Jae-Yong An CEO
 Chief Executive Officer 56 -
More insiders

ETFs positioned on SK bioscience Co.,Ltd.

Name Weight AuM 1st Jan change Investor Rating
KRANESHARES EMERGING MARKET HEALTHCARE INDEX ETF - DISTRIBUTING - USD ETF KraneShares Emerging Market Healthcare Index ETF - Distributing - USD
1.57% 2 M€ -14.14%
HAN-GINS INDXX HEALTHCARE MEGATREND EQUAL WEIGHT UCITS ETF - ACC - USD ETF HAN-GINS Indxx Healthcare Megatrend Equal Weight UCITS ETF - Acc - USD
0.78% 14 M€ -5.07%
NOMURA NEXT FUNDS EMERGING MARKET EQUITY MSCI-EM (UNHEDGED) ETF - JPY ETF Nomura NEXT FUNDS Emerging Market Equity MSCI-EM (Unhedged) ETF - JPY
0.04% 15 M€ +13.60%
More ETFs positioned on SK bioscience Co.,Ltd.

Quotes

Date Price Change Volume
24-05-31 51,700 -1.34% 242,151
24-05-30 52,400 -4.38% 184,975
24-05-29 54,800 -2.49% 132,430
24-05-28 56,200 -0.88% 78,400
24-05-27 56,700 +0.18% 60,225

End-of-day quote Korea S.E., May 30, 2024

More quotes

Company Profile

SK Bioscience Co Ltd is a Korea-based company mainly engaged in the manufacture and sale of biological products. The Company's main products include vaccines such as SKYCellflu and Rotatech. The Company also sells infusion solutions. In addition, the Company engages in technology export business. The Company sells its products in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-07-25 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for SK bioscience Co.,Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
51,700 KRW
Average target price
58,000 KRW
Spread / Average Target
+12.19%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
SK BIOSCIENCE CO.,LTD. Stock SK bioscience Co.,Ltd.
-28.19% 2.87B
CSL LIMITED Stock CSL Limited
-2.29% 89.87B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
-3.95% 37.57B
BIOGEN INC. Stock Biogen Inc.
-13.07% 32.75B
UCB Stock UCB
+63.05% 26.47B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-22.14% 14.25B
INCYTE CORPORATION Stock Incyte Corporation
-7.96% 12.99B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.33% 11.93B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-46.33% 10.84B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.77% 9.11B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. A302440 Stock